A pharma sponsor exploring decentralized clinical trials (DCT) for late-stage NSCLC integrated patient-first elements like in-home research nurses, telehealth via the IQVIA DCT Platform, and lab services to reduce patient burden across four countries. This approach improved engagement, adherence, and data quality while extending trial access beyond traditional sites. In a separate CRC sub-study, a “virtual site” model with mobile phlebotomy enrolled 1,094 patients in 16 months, expanding reach and improving specimen collection. Empathy mapping and flexible patient options enhanced retention, cut timelines, and enabled earlier detection of positive CRC cases.

Join for free to read